Topotecan in Combination With Pemetrexed in Patients With Advanced Malignancies

Lung Cancer Clinical Trial

Official title:

A Phase I Study of Topotecan in Combination With Pemetrexed in Patients With Advanced Malignancies

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00315861
• Other study ID #: SCRI REFMAL 72
• Secondary ID: 105114H3E-US-I01
• Status: Completed
• Phase: Phase 1
• First received: April 17, 2006
• Last updated: January 22, 2009
• Start date: March 2006
• Est. completion date: January 2009

Study information

• Verified date: January 2009
• Source: SCRI Development Innovations, LLC
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

Currently, no data exists regarding the safety and tolerability of a combination regimen utilizing weekly topotecan in combination with pemetrexed. Although both drugs are associated with myelosuppression, it is hoped that the utilization of the weekly topotecan dosing schedule will allow the drugs to be easily combined. This phase I trial will evaluate the safety and tolerability of weekly topotecan in combination with pemetrexed in patients with advanced solid tumors.

Description:

Three patients will be accrued at each of 5 dose levels. Dose escalation will only proceed if none of the additional 3 patients experience DLT. The highest dose level that generates DLT in 0/3 or 1/6 patients will be the maximum tolerated dose (MTD) or the doses recommended for subsequent studies. A total of 10 patients will be treated at the MTD to further assess the toxicity of the dosing regimen and its suitability for use in subsequent trials. Patients may continue to receive treatment until unacceptable toxicity or disease progression is encountered. Treatment cycles will be repeated every 21 days. The protocol is also designed to enroll an additional 10 patients at the maximum tolerated dose to increase the confidence in the safety and suitability of the doses that are chosen for subsequent studies.

• Topotecan Day 1 and 8

• Pemetrexed Day 1

Recruitment information / eligibility

• Status: Completed
• Enrollment: 15
• Est. completion date: January 2009
• Est. primary completion date: May 2008
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Histologically proven advanced solid tumors

• Measurable or evaluable disease

• Age = 18 years

• Karnofsky performance status = 80% (ECOG 0 or 1)

• Adequate liver, bone marrow and kidney function

Exclusion Criteria:

• More than 3 prior chemotherapy regimens in the metastatic setting

• Prior treatment with topotecan or pemetrexed

• Clinically significant third space fluid present at the time of treatment

• Unable to interrupt aspirin, other non-steroidal anti-inflammatory drugs

• Inability to take steroid premedications or vitamin supplementation

• The presence of active brain metastases

• Prior radiotherapy within 4 weeks prior to the first day of treatment

• Prior surgery within 3 weeks prior to the first day of treatment

• Prior chemotherapy within 3 weeks prior to the first day of treatment

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Cervical Cancer
• Endometrial Cancer
• Lung Cancer
• Ovarian Cancer
• Uterine Cervical Neoplasms

Intervention

Drug:
• pemetrexed

• topotecan

Locations

Country	Name	City	State
United States	Tennessee Oncology, PLLC	Nashville	Tennessee

Sponsors (3)

Lead Sponsor	Collaborator
SCRI Development Innovations, LLC	Eli Lilly and Company, GlaxoSmithKline

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	maximum tolerated doses of drugs in combination
Primary	overall toxicity of drug combination
Primary	preliminary antitumor activity of drug combination
Primary	impact of pemetrexed on topotecan pharmacokinetics